Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell ...
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma will ...
A live webcast of the presentation will be accessible via Caribou’s website on the Events page. The archived webcast will be available on the Caribou website for 30 days after the event. About ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 21 abstracts, including 5 oral presentations, ...
In a groundbreaking development for cancer treatment, Caribou Biosciences announced promising results from its off-the-shelf CAR-T therapy in patients with advanced B-cell lymphoma. This innovative ...
Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory ...
Regeneron has given up on a CAR-T candidate acquired from 2seventy bio last year before it entered the second part of a phase 1/2 lymphoma study. | Regeneron has given up on a CAR-T candidate acquired ...
From relapse to remission: Groundbreaking therapy gives Non-Hodgkin’s Lymphoma patients renewed hope
Doctors are turning to a groundbreaking new therapy; one that’s not only giving patients more healthy years, but in some ...
Brexucabtagene autoleucel approval marked a significant advancement in MCL treatment, achieving a 62% complete remission rate in resistant or relapsed patients. Prognostic tools like the Ki-67 index ...
When you start a medication like Dupixent (dupilumab), you expect relief from eczema or asthma, not the devastation of a cancer diagnosis. Yet ...
The integration of Bruton tyrosine kinase (BTK) inhibitors into first-line treatment regimens, in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback